The hot screening of the movie "I Am Not a Medicine God" has made more Chinese people aware of Indian generic drug companies, which are known as the "World Pharmacy" because of the mass production of high-quality and inexpensive generic drugs.
On September 24, Shanghai Sunshine Pharmaceutical Procurement Network released the results of the national organization of centralized drug procurement and use pilot national expansion, showing that the 25 "4+ 7" pilot drug expansion procurement were all successful. According to reports, the alliance procurement a total of 77 enterprises. There are 45 enterprises to be selected and 60 products to be selected. Compared with the minimum purchase price in the alliance area in 2018, the average price to be selected is reduced by 59%; compared with the "4+7" pilot price level, the average decrease is 25%.
The daily economic news (WeChat: nbdnews) reporter noted that the first time in this round of collection and expansion of the Indian generic drug enterprises - Dr. Ruidi Laboratory Co., Ltd. (dr. Reddy's, "Dr. Reddy") olanzapine tablets appeared at the second-lowest low price. Judging from the current quotation information, it is expected to be selected.
The entry of generic drugs in India has forced Chinese pharmaceutical companies to innovate
Due to the difference in patent protection standards for Chinese and Indian drugs, most of india's imitation oncology drugs have not entered the Chinese market through formal channels.
Recently, there have been rumors that Indian generic drug companies are ready to participate in the bidding for procurement, and on the 24th, Dr. Ruidi, an Indian pharmaceutical company, appeared at the bidding site, confirming such rumors.
"We are not surprised to see Indian pharmaceutical companies." The above-mentioned domestic pharmaceutical companies participating in the bidding said that this year, the relevant departments of the state and India have held a meeting on drugs, and domestic pharmaceutical companies have made psychological preparations.
In June this year, the "China-India Drug Regulatory Exchange Conference" was held in Shanghai. The meeting was co-sponsored by the State Drug Administration of China and the Central Drug Standards control authority of India. At the exchange meeting, the two sides conducted extensive exchanges on topics such as the laws and regulations, policies and technical requirements related to the registration of imported drugs in China and India, the guidelines for overseas inspection and compliance of drugs, the policies and processes of Drug Bidding and Procurement in China, and the cooperation between China and India in the pharmaceutical industry.
Image source: dr. Screenshot of reddy's official website
Indian pharmaceutical companies have also emerged in this collection and expansion. In the quotation of olanzapine tablets, Dr. Reddy became one of the three pharmaceutical companies with the lowest quotation at a price of 6.19 yuan / tablet (10mg), which was 35.8% lower than the "4 +7" winning bid price, higher than Qilu Pharmaceutical's 2.48 yuan / tablet, lower than Howsen Pharmaceutical's 6.23 yuan / tablet.
The above-mentioned domestic pharmaceutical companies believe that Indian generic drug companies have not entered the Chinese market in a large area before, which can actually be regarded as a protection for Chinese pharmaceutical companies. Because it competes with Indian generic drugs on the same stage, it is necessary to fight for both quality and price, and the strength of many Chinese generic drug companies needs to be improved. However, more and more Indian generic drug companies entering the Chinese market will become a development trend, which will correct the mentality of Chinese pharmaceutical companies in the production of generic drugs, and will also encourage pharmaceutical companies to accelerate innovation, so as to obtain better development space.
It is expected that the number of foreign-funded and joint ventures will increase to 7
Judging from the overall performance of the multinational pharmaceutical companies in this round of collection and expansion, some of the original pharmaceutical companies are relatively calm, and some multinational pharmaceutical companies are higher than the "4+7" urban collection and procurement prices. However, according to the requirements of this round of procurement, it is necessary to quote the ceiling of the "4+7" city collection price selection.
For such quotation behavior, some people in the pharmaceutical industry analyzed the daily economic news (WeChat: nbdnews) reporter, saying that there are both the influence of multinational pharmaceutical companies' quotation strategy factors and the psychological impact based on the advantages of previous original drugs. Before the consistency evaluation of generic drugs, there is a large gap between the efficacy of some domestic drugs and the original research drugs, which makes some people have the psychology that the efficacy of domestic generic drugs is not as good as the original research drugs, and this part of the people prefer to buy the original research drugs, so this psychology also gives some multinational pharmaceutical companies the living space of the original research drugs, so some original pharmaceutical companies are reluctant to reduce prices.
Some Chinese generic drug companies that won the bid in the last round of "4 + 7" procurement told the Daily Economic News (WeChat: nbdnews) reporter that after the bid, most of the markets in 11 cities were obtained, and some domestic generic drug companies were squeezed out of the market, but the sales of original pharmaceutical companies in some areas have achieved growth.
However, from an international point of view, after the expiration of the original drug patent, the birth of generic drugs generally brought about a cliff-like decline in the price of the original drug. "We still have to believe in Chinese generic drug companies that pass the consistency evaluation to enhance the trust of the people." The above-mentioned Chinese generic drug company said.
Of course, in the face of increasingly fierce competition, more and more multinational pharmaceutical companies are changing, seeking to exchange low prices for the market. During the "4+7" procurement pilot, foreign-funded and joint ventures won the bids for AstraZeneca (gefitinib tablets) and Shanghai Squibb Pharmaceuticals (Fosinopril tablets) in China and the United States, and according to the statistics of The Intranet, the number of foreign-funded and joint ventures that are expected to win the bid this time has increased to 7.
For example, the winning bidder of pemetrexed disodium "4+ 7" for injection is Sichuan Huiyu Pharmaceutical, with a winning bid price of 810 yuan / stick for 100mg / stick, the quotation of Eli Lilly is 809 yuan / stick, and the quotation of Sichuan Huiyu Pharmaceutical is 798 yuan / stick.
Clopidogrel bisulfate tablets "4 + 7" winning enterprise for Shenzhen Xinlitai, 75mg in the bid price of 3.18 yuan / piece, this time Sanofi quotation 2.55 yuan / tablet, CSPC Group quotation 2.44 yuan / tablet, Lepu quotation 2.98 yuan / tablet.